---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-046155"
form_type: "8-K"
ticker: "ELUT"
cik: "0001708527"
company_name: "ELUTIA INC."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T04:54:48.226705+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Elutia Issues Shares to Ligand, Amends SWK Loan, and Reports 84% Sequential EluPro Growth

## Summary
- Issued 1,105,528 shares to Ligand Pharmaceuticals to satisfy $2.2 million in royalty obligations.
- Amended SWK credit facility allowing full PIK interest in May 2025 and potential $5.0 million additional term loan.
- Reported Q1 2025 net sales of $6.0 million; BioEnvelope sales up 31% year-over-year to $3.1 million driven by 84% sequential EluPro growth.
- Entered partnership with Boston Scientific expected to accelerate EluPro adoption starting Q2 2025.
- Cash balance of $17.4 million as of March 31, 2025; raised $15.0 million in gross proceeds from direct offering.

## SEC filing metadata
- accession: 0001104659-25-046155
- form_type: 8-K
- ticker: ELUT
- cik: 0001708527
- company_name: ELUTIA INC.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 2.02, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708527/000110465925046155/0001104659-25-046155-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708527/000110465925046155/tm2514493d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-046155
- JSON: https://secwatch.observer/filing/0001104659-25-046155.json
- Plain text: https://secwatch.observer/filing/0001104659-25-046155.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.